How brain small vessel disease changes after lacunar or territorial stroke
Follows adults with brain small vessel disease after stroke, using scans and blood markers.
Plain-language title generated from the registry record
Registry title: Cerebral Small Vessel Disease Progression Dependent on Stroke Type
Key facts
- Where
- Ulm, GermanySee the site
Where in Germany
- University Hospital Ulm, Department of Neurology, GermanyUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johannes Dorst
- Trial code
- NCT07611136
- Record updated
- 28 May 2026
- Original description
The goal of this prospective, observational study is to understand if cerebral small vessel disease (CSVD) has different velocities and patterns of temporal development, dependent on a concurrent ischemic stroke. It focusses on adult patients with known or newly diagnosed CSVD on magnetic resonance imaging. The study will evaluate if blood based, in parts central nervous system specific protein markers, so called biomarkers, have an additional value reflecting the course of CSVD as defined per MRI assessments. Further patient-relevant endpoints include neuropsychological abilities, neurological functional outcomes, quality of life assessments, stroke recurrence risk.Read full original descriptionShow less
Biomarker-based Assessment of Cerebral Small Vessel Disease Progression After Lacunar and Territorial Stroke - a Prospective Cohort Study
The goal of this prospective, observational study is to understand if cerebral small vessel disease (CSVD) has different velocities and patterns of temporal development, dependent on a concurrent ischemic stroke. It focusses on adult patients with known or newly diagnosed CSVD on magnetic resonance imaging. The study will evaluate if blood based, in parts central nervous system specific protein markers, so called biomarkers, have an additional value reflecting the course of CSVD as defined per MRI assessments. Further patient-relevant endpoints include neuropsychological abilities, neurological functional outcomes, quality of life assessments, stroke recurrence risk.
Inclusion: Age ≥ 18 years; Evidence of cerebral small vessel disease on brain MRI, defined as white matter hyperintensities (Fazekas grade 1-3); Assignment to one of the following study groups based on MRI findings:; cerebral small vessel disease without evidence of an acute ischemic stroke; cerebral small vessel disease with acute lacunar ischemic stroke; cerebral small vessel disease with acute territorial ischemic stroke; Ability to provide written informed consent; Sufficient German language skills to understand study procedures and assessments.
Exclusion: Alternative plausible causes of white matter hyperintensities other than cerebral small vessel disease (e.g. inflammatory central nervous system disorders, leukodystrophies, brain tumors); Known neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, other dementias); Acute or recent traumatic brain injury; Contraindications to magnetic resonance imaging; Pregnancy or breastfeeding; Life expectancy of less than one year; Inability to comply with study procedures or follow-up visits.